A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor

Tara M. Stanne¹ Maja Olsson¹ Erik Lorentzen² Annie Pedersen¹ Anders Gummesson¹ Ann Gils³
Katarina Jood⁴ Gunnar Engström⁵ Olle Melander⁵ Paul J. Declerck³ Christina Jern¹

¹Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

²Bioinformatics Core Facility, University of Gothenburg, Gothenburg, Sweden

³Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Brussels, Belgium

⁴Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

⁵Department of Clinical Sciences, Lund University, Lund, Sweden

Address for correspondence: Tara Stanne, PhD, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Box 445, SE-405 30 Gothenburg, Sweden (e-mail: tara.stanne@gu.se).

Thromb Haemost 2018;118:298–308.

Abstract

Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a central role in haemostasis, and plasma TAFI concentrations are heritable. Candidate gene studies have identified several variants within the gene encoding TAFI, *CPB2*, that explain part of the estimated heritability. Here, we describe an exploratory genome-wide association study to identify novel variants within and outside of the *CPB2* locus that influence plasma concentrations of intact TAFI and/or the extent of TAFI activation (measured by released TAFI activation peptide, TAFI-AP) amongst 3,260 subjects from Southern Sweden. We also explored the role of rare variants on the HumanExome BeadChip. We confirmed the association with previously reported common variants in *CPB2* for both intact TAFI and TAFI-AP, and discovered novel associations with variants in putative *CPB2* enhancers. We identified a gene-based association with intact TAFI at *CPB2* ($P_{\text{SKAT-O}} = 2.8 \times 10^{-8}$), driven by two novel rare nonsynonymous single nucleotide polymorphisms (SNPs; I420N and D177G). Carriers of the rare variant of D177G (rs140446990; MAF 0.2%) had lower intact TAFI and TAFI-AP concentrations compared with non-carriers (intact TAFI, geometric mean 53 vs. 78%, $P_{\text{T-test}} = 5 \times 10^{-7}$; TAFI-AP 63 vs. 99%, $P_{\text{T-test}} = 7.2 \times 10^{-4}$). For TAFI-AP, we identified a genome-wide significant association at an intergenic region of chromosome 3p14.1 and five gene-based associations (all $P_{\text{SKAT-O}} < 5 \times 10^{-6}$). Using well-characterized assays together with a genome-wide association study and a rare-variant approach, we verified *CPB2* to be the primary determinant of TAFI concentrations and identified putative secondary loci (candidate variants and genes) associated with intact TAFI and TAFI-AP that require independent validation.

Keywords

- thrombin-activatable fibrinolysis inhibitor
- fibrinolysis inhibitors
- plasma levels
- genome-wide association study

received
April 10, 2017
accepted after revision
November 10, 2017

DOI <https://doi.org/10.1160/TH17-04-0249>.
ISSN 0340-6245.

Copyright © 2018 Schattauer

License terms

Introduction

Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as procarboxypeptidase U and procarboxypeptidase B, plays a central role in haemostasis where it acts as a potent inhibitor of fibrinolysis.¹ More recently, a role for TAFI in regulation of inflammation, cell migration and wound healing has also been described.² The TAFI zymogen is secreted by the liver into the circulation. A single cleavage at Arg92 by thrombin, plasmin, or the thrombin–thrombomodulin complex removes the activation peptide (TAFI-AP; Phe1-Arg92; 20 kDa) and makes the active site accessible to substrates (active TAFI or TAFIa; Ala93-Val401; 36 kDa^{3,4}). TAFIa can then inhibit fibrinolysis by removing carboxy-terminal lysine residues from partially degraded fibrin, which results in a decreased plasminogen binding and decreased fibrinolytic activity.⁵ TAFIa is inactivated through a conformational change to an inactive form (TAFIai) which is subsequently cleaved resulting in two smaller fragments of 25 and 11 kDa.⁶ Plasma TAFI levels have been reported to show association with deep-vein thrombosis,^{7,8} coronary artery disease,^{9,10} and ischaemic stroke.^{11–13}

Most quantitative studies of TAFI have focused on ‘total’ antigen levels (TAFI-Ag) and used assays which recognize the intact, nonactivated TAFI (i.e. zymogen) as well as the various cleavage products. In healthy individuals, plasma levels of TAFI have been shown to be stable over time but exhibit a large interindividual variability poorly explained by lifestyle and environmental factors.¹⁴ Family studies have demonstrated that plasma TAFI levels are heritable (heritability estimates ranging from 40 to 70% for TAFI-Ag and 16% for TAFIa activity^{15–20}), suggesting a strong genetic component. Several common single nucleotide polymorphisms (SNPs) located within the gene encoding TAFI (*CPB2*) have been described (including two that result in amino acid substitutions: Thr147Ala [rs3742264] and Thr325Ile [rs1926447]), and some are reported to be associated with plasma TAFI-Ag, TAFI-AP and/or TAFIa concentrations and risk of arterial and venous thrombotic disease.^{7–13,21–23} It should be stressed, however, that the immunological assays used in most of these studies were not validated with respect to putative differential reactivities toward different isoforms of TAFI and cleavage product fragments of TAFI. In particular, Thr325Ile can have a large impact on immunoreactivity.^{24,25} Thus, reported clinical effects associated with TAFI SNPs and protein levels as well as heritability estimates should be treated with caution (see ►Supplementary Table S1 for overview). Genome-wide linkage studies confirmed the *CPB2* locus to be a strong determinant of TAFI-Ag^{18,20} and TAFI activity¹⁸ levels and found weak evidence for additional linkage on other autosomal loci.^{18,20} However, no high-resolution genome-wide association study (GWAS) has been reported; therefore, the exact genetic basis for the heritability remains unknown.

We hypothesized that there are *cis*- and *trans*-acting loci in addition to the previously identified *CPB2* variants that contribute to the variation in circulating TAFI levels. Furthermore, we hypothesize that rare or low-frequency variants, which are not well covered by GWAS and not easily imputed, in addition to common variants are associated with TAFI levels. Here, we

used two well-characterized immunological assays, validated to be isoform independent, which react to the intact nonactivated TAFI, or to the activation peptide (TAFI-AP, a marker of the extent of TAFI activation²⁶). In this explorative study, we tested our hypothesis using a genotyping platform that is enriched with exome content (HumanExome BeadChip) and we searched for both common and rare genetic variants associated with intact TAFI and TAFI-AP levels in data from 3,260 Swedish adults.

Materials and Methods

Study Design

We performed a GWAS and gene-based analyses of plasma TAFI (intact and AP) in a subset of participants from the southern Swedish study on ischaemic stroke.²⁷ The present study included European ancestry participants with genetic data and in whom plasma levels of TAFI had been measured or citrate plasma was available for analyses. These participants included 600 cases with ischaemic stroke at ages 18 to 69 years and 600 controls matched for age and sex from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLIS²⁸) and 2,060 population-based participants from the prospective Malmö Diet and Cancer Study (MDC²⁹) of whom 1,812 have not had a cardiovascular event and 248 had an ischaemic stroke during follow-up. The designs of these studies are described in the ►Supplementary Material. Sample sizes, mean age and sex distribution of study participants in each cohort at the time of the intact TAFI and TAFI-AP determination are summarized in ►Table 1.

Both participating cohorts were granted approval by the appropriate research ethics committees for the research (MDC: LU51/90, 166/2007 and 633/2009; and SAHLIS: University of Gothenburg Ö-469–99, T-553–03, 873–11 and 823–13). All participants or their next of kin provided written informed consent.

TAFI Antigen and Activity Measurement

Venous blood samples were collected after an overnight fast in tubes containing 10% volume of 0.13 mol/L sodium citrate. For the MDC study, samples were drawn 2 to 4 months after enrolment. For SAHLIS, blood sampling was performed once for controls and during the convalescent phase at 3-month follow-up for stroke patients.²⁸ Aliquots of plasma were stored at –80°C. Plasma levels of TAFI were measured by an ELISA which recognizes intact TAFI and equally recognizes the common TAFI isoforms and an ELISA specifically measuring the activation peptide (amino acids residues 1–92, TAFI-AP²⁶). All analyses were performed in the same laboratory. Values are expressed relative to pooled human plasma (%). Intra- and inter-assay coefficients of variation were 6.2 and 8.3%, respectively, for intact TAFI, and 3.1 and 7.3%, respectively, for TAFI-AP. Intact TAFI and TAFI-AP data were naturally log transformed for analysis.

Genotyping, Imputation and Quality Control

DNA was extracted from whole blood and genotyping was performed with either the HumanOmniExpress Exome BeadChip v1.0 at the Broad Institute (SAHLIS: *n* = 756; MDC: *n* = 2,060) or the HumanOmni 5M Exome v1.0 as part of the

Table 1 Subject characteristics at the time of blood sampling and genotyping chip used

	MDC (<i>n</i> = 2,060)	SAHLSIS (<i>n</i> = 756)	SAHLSIS ^a (<i>n</i> = 444)	Total (3,260)
Cases, <i>n</i> (%)	0 (0)	166 (22)	444 (100)	600 (18.4)
Age, median (IQR)	58 (53–63)	59 (52–64)	58 (50–63)	58 (52–64)
Male gender, <i>n</i> (%)	818 (39.7)	477 (63.1)	293 (66)	1,588 (48.7)
Hypertension, <i>n</i> (%)	1,304 (63)	333 (44.2)	245 (56.1)	1,882 (57.9)
Diabetes mellitus, <i>n</i> (%)	192 (9.3)	66 (8.8)	81 (18.2)	339 (10.4)
Current smoking, <i>n</i> (%)	405 (22.4)	174 (23)	168 (38)	792 (24.7)
Hyperlipidaemia, <i>n</i> (%)	1,847 (90.2)	512 (69.3)	304 (75.1)	2,663 (83.4)
Intact TAFI, <i>n</i> (%)	2,052 (99.6)	748 (98.9)	404 (91.0)	3,204 (98.3)
Median (IQR)	72 (61–85)	90 (77–101)	95 (83–114)	79 (65–95)
TAFI-AP, <i>n</i> (%)	2,060 (100)	748 (98.9)	404 (91.0)	3,212 (98.5)
Median (IQR)	96 (67–132)	105 (93–122)	124 (105–148)	103 (80–131)
Genotyping platform	Human OmniExpress Exome v1.0	Human OmniExpress Exome v1.0	Human Omni 5M Exome v1.0	Imputed to the UK10K + 1000 Genomes Ph3

Abbreviations: MDC, Malmö Diet and Cancer Study; SAHLSIS, Sahlgrenska Academy Study on Ischemic Stroke; TAFI-AP, thrombin-activatable fibrinolysis inhibitor activation peptide.

Note: Intact TAFI expressed as relative levels; TAFI-AP, TAFI activation peptide, expressed as relative levels.

^aIncluded in the NINDS Stroke Genetic Network (SiGN) study.

Stroke Genetics Network (SiGN) study (SAHLSIS: *n* = 444; Illumina, San Diego, California, United States) as described.^{27,30} These arrays have an overlap the Omni content for coverage of common genome-wide variation and both contain an overlapping exome content set of 240k probes (HumanExome BeadChip). Nonoverlapping sites were ignored. Genotypes for the GWAS were auto-called with the Illumina GenomeStudio v2011.1 software and the GenTrain2.0 clustering algorithm. Genotypes for the gene-based tests on rare variants were called using a combination of auto-call and Z-call.³¹ The quality control criteria performed by each study for filtering of poorly genotyped individuals and low-quality SNPs included a call rate of <0.95, gender mismatch, identity by descent sharing (>0.375, second-degree relatives), population outliers, excess autosomal heterozygosity and deviation from Hardy-Weinberg equilibrium ($P < 10^{-3}$). After separate quality check, the overlapping 731k variants from each dataset were merged and rechecked for quality using the aforementioned criteria. Imputation was performed on autosomal chromosomes, after excluding monomorphic and tri-allele SNPs, in the merged dataset using the UK10K + 1,000 Genomes Phase 3 reference panel at the Sanger Imputation Service.³² Prior to imputation, each chromosome was phased against the hg19/GRCh37 reference panel using SHAPEIT2 (v2.r790³³). Imputed variants with information score greater than 0.3 were included resulting in approximately 10 million autosomal variants with MAF greater than 1%. The total numbers of subjects included in the analysis were 3,116 for intact TAFI and 3,124 for TAFI-AP.

Genome-wide Association Analyses

Genotype–phenotype association analyses were performed according to a prespecified analysis plan on autosomal variants

with a minor allele frequency (MAF) >1%. The association of SNP with natural logarithm-transformed intact TAFI or TAFI-AP values was assessed by a linear model, assuming an additive effect of each risk allele, using PLINK version 1.9. All analyses were adjusted for age, sex, and case–control status. The β value represents the per-allele effect on the natural log-transformed intact TAFI or TAFI-AP concentration. The prespecified threshold of genome-wide significance was set at the conventional level of $P = 5 \times 10^{-8}$. Suggestive associations were defined as $P < 10^{-6}$. Based on our sample size and assuming an additive model, the minimal effect size (β -coefficient, β , expressed as standard deviation increase in log-transformed plasma concentration) per allele that is detectable with 80% power at $P = 5 \times 10^{-8}$ is 0.175 for MAF 30%, 0.26 for MAF 10%, 0.37 for MAF 5% and 0.79 for MAF 1%.

We performed conditional analyses to control for the effects of the lead SNP at the *CPB2* locus for intact TAFI as well as for TAFI-AP. The allele dosage (0–2 copies based on imputed genotypes) of the lead variant was used as a covariate in these analyses. For intact TAFI, a significant signal remained; therefore, an additional model was also computed that corrected for the lead SNP from the initial analysis as well as the lead SNP from the conditional analysis (i.e. corrected for two independent SNPs).

Gene-Based Analyses

Gene-based tests are designed to gain power, especially for analyses of variants with low MAF, by aggregating the association signals from variants within the same gene. Thus, we used gene-based tests to investigate the role of rare (MAF < 0.5%) and low-frequency (MAF 0.5% to 5%) variants on intact TAFI and TAFI-AP concentrations. All directly genotyped functional

variants (missense, nonsense and splice variants) that overlapped between the datasets with MAF <5% and which passed quality check were included in the gene-based tests (48,898 variants in total). All genes were required to contain at least two variants to be included in the analysis and to have a cumulative minor allele count of ≥ 4 (resulting in 9,325 genes in total). Gene-based tests for association with natural log-transformed intact TAFI and TAFI-AP concentrations were performed using the optimal combination of the sequence kernel association test and the burden test (SKAT-O³⁴), in R package 'SKAT' version 1.0.7 (<https://cran.r-project.org/web/packages/SKAT/>), using the internal settings kernel = linear, weighted and method = optimal adj, adjusting for age, sex and case-control status. A Bonferroni-corrected, gene-based *P*-value threshold of 5.36×10^{-6} was used for gene-based tests (0.05/9,325 genes). Suggestive associations for the gene-based analyses were defined as $P < 10^{-4}$. For significant findings, genotype intensity cluster plots were visually inspected and rare variants were annotated with the most current MAF data from the Exome Aggregation Consortium (ExAc).

Annotation and Functional Prediction of Variants

As gene enhancer elements play a central role in regulating transcription, we speculated that many of the variants remaining in the conditional analysis of intact TAFI may

be in high linkage disequilibrium (LD) with or located within putative enhancer elements. The GeneHancer database, embedded in GeneCards (www.genecards.org), was used to identify 14 putative enhancer elements (see ► **Supplementary Table S2** for regions). We then used SNAP (SNP Annotation and Proxy Search; Broad Institute), to find proxy SNPs for the 69 variants with MAF greater than 1% located within these regions, based on LD information from the 1000 Genomes Project CEU population and an R^2 threshold of >0.8 . The ► **Supplementary Tables** are annotated with this information.

Furthermore, we used publicly available expression quantitative trait locus (eQTL) browsers to see whether any of the identified variants were eQTLs for genes of interest. For each lead variant within a significant or suggestive locus (listed in ► **Table 2**), we investigated associations between genotype and expression levels of all genes located within ± 200 kb of the variant, in all available tissues. The browsers and available tissue types used were as follows: the eQTL browser of the Genotype-Tissue Expression (GTEx, accessed December 2016) project includes more than 70 tissue types including liver and whole blood,³⁵ and the eQTL resources from the Gilad/ Pritchard group includes liver tissue as well as several other tissue types³⁶ and the blood eQTL browser based on peripheral blood.³⁷

Table 2 Genome-wide and suggestive loci ($P < 10^{-6}$) for intact TAFI and the TAFI activation peptide (TAFI-AP, a marker of the extent of TAFI activation)

Region	Most significant	Effect allele	Alternate allele	MAF	<i>P</i> -Value	Beta	SE	Closest genes
Intact TAFI								
13q14.13	rs56734909	A	C	0.343	5.3E-30	0.09	0.008	CPB2
5q22.1	rs11743286	T	A	0.022	3.0E-07	-0.15	0.030	TMEM232/SLC25A46
12q24.21	rs78402106	C	T	0.017	4.9E-07	-0.15	0.030	TBX5/RBM19
2p25.3	rs570398477	C	T	0.011	5.1E-07	-0.18	0.037	SNTG2/TPO
12q24.31	rs117742602	G	A	0.011	7.0E-07	-0.19	0.038	DENR/HCAR1/HCAR3
5p15.31	rs189859825	C	T	0.033	9.8E-07	0.11	0.022	SEMA5A/MIR4636
TAFI-AP								
13q14.13	rs940	G	C	0.235	1.0E-27	0.16	0.014	CPB2
3p14.1	rs140102162	G	A	0.011	1.3E-08	-0.39	0.069	MIR4272/KBTBD8/SUCLG2
11p11.2	rs745770348	A	ACC	0.016	2.8E-07	-0.27	0.053	CD82/TSPAN18/ALX4
16q12.2	rs117122953	T	C	0.012	3.8E-07	-0.33	0.064	IRX5/CRNDE/IRX6
9q33.3	rs79740971	A	G	0.017	4.0E-07	-0.28	0.055	DENND1A/LHX2
3p26.1	rs80062757	T	G	0.013	4.4E-07	-0.31	0.062	BHLHE40/ITPR1/EGOT
16p12.2	rs78970023	A	T	0.015	4.7E-07	-0.27	0.053	OTOA/METTL9/IGSF6
15q25.3	rs111511310	T	C	0.025	5.5E-07	-0.22	0.045	LOC101929701/AGBL1/KLHL25
2q36.2	rs4674940	G	A	0.032	6.0E-07	-0.17	0.035	DOCK10/MIR4439/CUL3
3p22.3	rs150338049	A	AGCAAG	0.092	8.8E-07	0.11	0.023	ARPP21/MIR128-2/LOC101928135
11p14.2	rs113021326	T	C	0.016	9.0E-07	-0.27	0.054	FIBIN/SLC5A12/ANO3

Abbreviations: TAFI-AP, thrombin-activatable fibrinolysis inhibitor activation peptide.

Note: Intact TAFI, expressed as relative levels; TAFI-AP, expressed as relative levels.

Statistical Analysis

We used a linear regression model to determine the variance in intact TAFI and TAFI-AP in healthy controls, explained by cardiovascular risk factors (smoking, hypertension, hyperlipidaemia and diabetes mellitus), anthropometric measures (body mass index and waist hip ratio) and high sensitivity C-reactive protein (hsCRP). Likewise, to determine the variance in intact TAFI and TAFI-AP explained by the three covariates included in the GWAS model (age, sex and case-control status), we used linear regression. We then performed a model conditioned on these covariates to determine the remaining variance explained by a particular variant or variant combination.

Results

We conducted a GWAS and additionally evaluated rare and low-frequency functional variants using gene-based tests in 3,260 individuals of European ancestry to identify genetic loci influencing concentrations of circulating intact TAFI and TAFI-AP (a measure of the extent of TAFI activation). Characteristics of participants, genotyping arrays used, and median and interquartile range for each TAFI measure per cohort are summarized in ►Table 1. In our study population, cardiovascular risk factors and anthropometric measures explained very little of the variance in intact TAFI or TAFI-AP concentrations, in line with previous reports (1.7 and 3.6% in controls, respectively). The two TAFI traits were moderately correlated (Spearman's $Rho = 0.33$, $P < 0.001$) in our study population, also in line with previous studies.²⁶

Genome-wide Association Study

Intact Thrombin-Activatable Fibrinolysis Inhibitor

In total, 10M imputed autosomal variants with MAF greater than 1% were included in the GWAS. The genomic control coefficient was close to 1 ($\lambda = 1.02$), which suggests negligible test-statistic inflation. For intact TAFI, 325 SNPs in a region of chromosome 13 passed the genome-wide significance threshold (►Fig. 1 and ►Supplementary Table S3). All SNPs were within or close to the *CPB2* gene, which encodes TAFI (►Fig. 1C) and the overlapping antisense long noncoding RNA (lncRNA) *CPB2-AS1*. As gene enhancer elements play a central role in regulating transcription, we annotated variants listed in ►Supplementary Table S3 to indicate SNPs located within the 14 putative enhancer elements of the *CPB2* gene and SNPs in high LD with SNPs in putative enhancers. Rs56734909 had the smallest P -value (5.3×10^{-30}) and is located within a predicted *CPB2* enhancer (GeneHancer ID GH130046105). It is also in high LD ($R^2 = 0.96$; $D' = 1$) with a *CPB2* promoter SNP, previously shown to associate with TAFI-Ag concentrations ($-2599C > G$, rs34813434).^{22,38,39} The A allele (frequency, 66%) of rs56734909 was associated with higher intact TAFI levels. Over a third of the remaining SNPs were within ($n = 33$) or in high LD ($n = 87$) with putative *CPB2* enhancers (►Supplementary Table S3).

An additional six SNPs outside of the *CPB2* locus were suggestively associated ($P < 10^{-6}$) with intact TAFI concentrations, and marked five regions on three chromosomes: 5q22.1, 12q24.21, 2p25.3, 12q24.31 and 5p15.31. Each of these regions had solitary suggestive SNP associations, with the exception of 2p25.3 which had two suggestive SNP associations. It is of note

Fig. 1 Genome-wide association analyses of intact TAFI. (A) Manhattan plot of associations. Dotted line shows genome-wide significance (5×10^{-8}). (B) QQ-Plot. (C) Regional association plot of chromosome 13, *CPB2* locus. (D) Regional association plot of *CPB2* locus in a conditional analysis adjusted for the lead SNP, rs56734909. (E) Regional association plot in a further conditional analysis adjusted for rs56734909 and rs1087.

Fig. 2 Genome-wide association analyses of TAFI activation peptide. (A) Manhattan plot of associations. Dotted line shows genome-wide significance (5×10^{-8}). (B) Q-Q-Plot. (C) Regional association plot of chromosome 13, *CPB2* locus. (D) Regional association plot of *CPB2* locus in a conditional analysis adjusted for the lead SNP, rs940. (E) Regional association plot of rs140102162 on chromosome 3.

that chromosome region 5p15 was previously identified as a suggestive locus in a linkage analysis of TAFI-Ag; however, no obvious candidate genes are present at that locus.¹⁸ ▶ **Table 2** lists the results for the lead SNP at these loci and regional plots can be found in ▶ **Supplementary Fig. S1**.

To determine whether multiple independent signals were present in the *CPB2* locus (chr13: pos 46.5–46.7Mb), a secondary analysis was conducted conditioned on the lead SNP. After adjustment for rs56734909, 93 variants in the 13q14.11 region retained genome-wide significance (▶ **Fig. 1D**; ▶ **Supplementary Table S4**). This suggests there are at least two independent SNPs in the *CPB2* locus that regulate intact TAFI concentrations. We hypothesized that the remaining signal may be due to SNPs in high LD with or located within the 14 putative enhancer elements of the *CPB2* gene and annotated in ▶ **Supplementary Table S4** with this information. Of the 93 associated SNPs, the majority were indeed either in predicted *CPB2* enhancers ($n = 13$) or in high LD ($R^2 < 0.8$; $n = 44$) with predicted *CPB2* enhancer variants (▶ **Supplementary Table S4**). Rs1087 had the smallest $P_{\text{conditional}}$ value (2.63×10^{-11}), but this variant is not located in any putative enhancers nor is it in LD with any SNPs located within enhancers. Rather, rs1087 is located in the *CPB2* 3' UTR and has previously been shown to associate with TAFI-Ag levels ($+1583T > A$),^{22,38–40} through affecting mRNA stability.^{41,42} The A allele (frequency, 35%) of rs1087 was associated with higher intact TAFI levels. The variance in intact TAFI explained by age, sex and case-control status is 8.7%. The lead SNP (rs56734909) on its own explained 4% of the remaining variance and together with rs1087, 5.4% of the remaining variance was explained.

When conditioning the remaining SNPs in the *CPB2* locus on both rs56734909 and rs1087, we found an independent SNP that did not reach genome-wide significance but suggests complex genomic structure at this locus (rs17844119, $P_{\text{conditional}}$ value = 0.0001, ▶ **Fig. 1E**).

In an effort to identify putative candidate genes from the genome-wide significant and suggestive lead variants, we interrogated public regulatory annotation datasets using the lead SNP from each locus. None of our lead variants were eQTLs for any gene in any of the available tissues (data not shown), with the exception of rs1087 in the conditioned analysis which was an eQTL for the lncRNA *CPB2-AS1* in four tissues (cerebellum, $P_{\text{GTEX}} = 1.6 \times 10^{-6}$, $\beta_{\text{GTEX}} = -0.59$; basal ganglia, $P_{\text{GTEX}} = 2.0 \times 10^{-7}$, $\beta_{\text{GTEX}} = -0.63$; pituitary, $P_{\text{GTEX}} = 9.1 \times 10^{-6}$, $\beta_{\text{GTEX}} = -0.68$; and thyroid, $P_{\text{GTEX}} = 1.8 \times 10^{-5}$, $\beta_{\text{GTEX}} = -0.33$).

Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide

The genomic control coefficient for the TAFI-AP GWAS was close to 1 ($\lambda = 0.996$). For TAFI-AP, two loci reached the genome-wide significance threshold of 5×10^{-8} (▶ **Fig. 2**). ▶ **Table 2** lists the top variants for each chromosomal region. For the first locus, we identified numerous SNPs ($n = 316$) of genome-wide significance in the 13q14.11 region that harbours the *CPB2* gene and antisense transcript *CPB2-AS1*. The lead SNP (rs940, $P = 1 \times 10^{-27}$) resides within the *CPB2* 3' UTR. This SNP has previously been shown to associate with TAFI-Ag levels ($+1542C > G$)²² and was significantly associated with intact TAFI levels in our dataset as well ($P = 6.62 \times 10^{-16}$). A regional plot for rs940 can be found in ▶ **Fig. 2C**. This SNP is in perfect LD with several SNPs predicted to be located within

two *CPB2* enhancer elements (rs2897027, GH130046061; rs2296641, rs3783202 and rs1409435, all in GH130046056), but is not itself located in an enhancer. It is also in high LD with the 3' UTR SNP identified in the conditional analysis of intact TAFI (rs1087; $D' = 1.0$, $R^2 = 0.13$, based on the 1000 Genomes Project CEU population). The G allele (frequency, 76.5%) of rs940 was associated with higher TAFI-AP levels. When the data were reanalysed conditioning on rs940, we found an independent SNP that did not reach genome-wide significance (**Fig. 2D**; smallest $P_{\text{conditional}}$ value = 1.7×10^{-5} , rs7491577). The variance in TAFI-AP explained by age, sex and case-control status is 4.2%. The proportion of variance in natural log-transformed TAFI-AP (above age, sex and case-control status) explained by rs940 is 3.8%.

The second genome-wide significant locus for TAFI-AP was at chromosomal position 3p14.1 (rs140102162, P -value 1.310^{-8} , **Table 2**). This was a solitary SNP association in an intergenic region between the *KBTBD8* (kelch repeat and BTB domain containing 8) and the *SUCLG2* (Succinate-CoA Ligase GDP-Forming Beta Subunit) genes (**Fig. 2E**).

An additional 9 loci, composed of 14 SNPs, were suggestively associated ($P < 10^{-6}$) with TAFI-AP (**Table 2**, **Supplementary Table S5**, **Supplementary Fig. S2**). Chromosomal position 16p12.2 contained three suggestive SNPs in the *OTOA* gene, which encodes the otoancorin protein and is expressed in the inner ear and in T-lymphocytes. Rs78970023, the lead SNP ($P = 4.7 \times 10^{-7}$), is a missense SNP that leads to a phenylalanine-tyrosine (F15Y) substitution. Chromosomal position 2q36.2 contained four SNPs within the *DOCK10* (dedicator of cytokinesis 10) gene. Rs4674940, the lead SNP with (P -value 6.0×10^{-7}), is located within an exon and leads to a synonymous substitution. The other loci contained only one suggestive SNP each.

When we interrogated public regulatory annotation datasets using the lead SNP from each genome-wide significant and suggestive locus for TAFI-AP to identify putative candidate genes, none of our lead variants were found to be eQTLs for any gene in any of the available tissues (data not shown), with the exception of rs940 which was an eQTL for *CPB2-AS1* in EBV-transformed lymphocytes ($P_{\text{GTEx}} = 1.4 \times 10^{-5}$, $\beta_{\text{GTEx}} = 0.44$).

Gene-Based Analysis

Gene-based tests were used to test for aggregation of low-frequency and rare variants in genes that may have importance for intact TAFI or TAFI-AP. The only significant association that contributed to plasma-level variation in intact TAFI was the *CPB2* gene itself ($P_{\text{SKAT-O}} = 2.75 \times 10^{-8}$, **Table 3**). *CPB2* remained associated with intact TAFI after conditioning on the lead SNP from GWAS (rs56734909; $P_{\text{conditional}} = 1.86 \times 10^{-6}$). Two markers comprised the signal: rs145067962 (Ile420Asn; MAF, 0.15%; MAF_{ExAC} 0.14%) and rs140446990 (Asp177Gly; MAF, 0.20%; MAF_{ExAC} 0.13%). Carriers of the rs140446990 mutation had significantly lower intact TAFI levels than non-carriers ($n = 14$ carriers vs. $n = 3,190$ noncarriers; geometric mean 52.7 vs. 78.5%; $P_{\text{T-test}} = 5.08 \times 10^{-7}$). This was true for both ischaemic stroke cases ($n = 4$ carriers vs. $n = 550$ noncarriers; geometric mean 68.4 vs. 94.8%; $P_{\text{T-test}} = 0.008$) and controls ($n = 10$ carriers vs. $n = 2,640$ noncarriers; geometric mean

Table 3 Intact TAFI and TAFI activation peptide (TAFI-AP): significant and suggestive loci from gene-based tests (SKAT-O)

Gene	P-Value	Nr SNPs	Region
Intact TAFI			
<i>CPB2</i>	2.8E-08	2	13q14.13
<i>PHLDB2</i>	1.1E-05	5	3q13.2
<i>SEC14L4</i>	2.9E-05	2	22q12.2
<i>GDPGP1</i>	6.2E-05	2	15q26.1
TAFI-AP			
<i>SGPL1</i>	8.3E-07	3	10q22.1
<i>OTOA</i>	2.5E-06	2	16p12.2
<i>ADAL</i>	3.3E-06	2	15q15.3
<i>GAST</i>	3.5E-06	2	17q21.2
<i>TOR1B</i>	4.1E-06	3	9q34.11
<i>CPB2</i>	7.2E-06	2	13q14.13
<i>MLN</i>	6.6E-05	2	6p21.31

Abbreviations: TAFI-AP, thrombin-activatable fibrinolysis inhibitor activation peptide.

Note: Intact TAFI, expressed as relative levels; TAFI-AP, TAFI activation peptide expressed as relative levels.

47.4 vs. 75.4%; $P_{\text{T-test}} = 4.78 \times 10^{-7}$). No difference in intact TAFI values was observed for rs145067962 carriers and noncarriers (data not shown). To determine whether this variant in *CPB2* was independent of the two more common amino acid substitutions, we instead conditioned on Thr147Ala (rs3742264) and Thr325Ile (rs1926447) and found that the variant remained significant ($P_{\text{conditional}} = 1.66 \times 10^{-6}$), suggesting that the observed rare variant associations are distinct from known SNPs.

In contrast to intact TAFI, for TAFI-AP SKAT-O yielded significant gene-level associations with five genes (**Table 3**) and only near significance with *CPB2* ($P_{\text{SKAT-O}} = 7.18 \times 10^{-6}$). The strongest associated gene was *SGPL1* (sphingosine-1-phosphate lyase 1), followed by *OTOA* (described earlier), *ADAL* (adenosine deaminase-like), *GAST* (gastrin) and *TOR1B* (torsin family 1 member B). Of note, the variant driving the association at *OTOA* in SKAT-O is the same as the lead GWAS SNP at this locus. *SGPL1* ($P_{\text{SKAT-O}} = 8.33 \times 10^{-7}$) encodes the enzyme sphingosine phosphate lyase (SPL) which plays a critical role in the regulation of sphingosine-1-phosphate (S1P), a versatile lipid-signaling molecule. Three variants within *SGPL1* comprised the signal: K228N, rs191033522, MAF 0.02%, MAF_{ExAC} 0.03%; Y356C, rs147860288, MAF 0.03%, MAF_{ExAC} 0.03%; and Y374C, rs139751906, MAF 0.03%, MAF_{ExAC} 0.02%. Only five individuals were carriers of any of these variants; carriers of the minor allele of rs191033522 and rs139751906 had lower TAFI-AP concentrations compared with noncarriers, while carriers of rs147860288 had elevated TAFI-AP concentrations. With regard to *CPB2*, similar to intact TAFI, carriers of the rs140446990 (Asp177Gly) mutation had significantly lower TAFI-AP levels than noncarriers ($n = 14$ vs. $n = 3,198$ noncarriers; geometric mean 63 vs. 99%, $P_{\text{T-test}} = 7.2 \times 10^{-4}$).

Discussion

This is the first GWAS to examine genetic determinants of intact TAFI and the extent of TAFI activation (measured by TAFI-AP) in plasma. Using a TAFI assay that reacts exclusively to the nonactivated intact TAFI and equally recognizes the common TAFI isoforms, we verified *CPB2* at the 13q14.11 locus to be the strongest determinant of intact TAFI concentrations. However, less of the variation was explained for both intact TAFI and TAFI-AP than previously reported for 'total' TAFI, denoted TAFI-Ag. Furthermore, we identified an additional genome-wide significant locus for TAFI-AP. We then performed gene-based tests to investigate the role of rare and low-frequency variants and identified novel low frequency coding variants within *CPB2* associated with intact TAFI concentrations as well as completely novel associations for TAFI-AP to five genes. As these results are explorative in nature, the novel associations outside the 13q14.11 locus require independent validation.

With regards to the GWAS, the strongest associations for intact TAFI and TAFI-AP concentrations were for variants located in the 13q14.11 locus and both analyses indicate a complex genomic architecture at this locus. Common *CPB2* SNPs have been known to influence TAFI levels for some time and early linkage studies also implicated this region.^{18,20} Thus, in spite of using a larger sample size and modern techniques including dense imputation, we still find this to be the primary locus, and somewhat unexpectedly we did not identify common variants at any other autosomal region with similar estimated effect sizes. For intact TAFI, two independent genome-wide variants in the *CPB2* locus were identified: one in the 5' UTR of the gene (rs56734909) located in a putative enhancer element and one in the 3' UTR (rs1087). This is consistent with previous studies that suggested that two polymorphisms in *CPB2*, one in the promoter region and the other in the coding or 3' region, likely underlie the variation in TAFI-Ag.^{38,43} A *trans*-ethnic haplotype study revealed rs1087 to be the most likely eQTL in the 3' region for TAFI-Ag,³⁹ supported also by mRNA stability experiments.^{41,42} The identification of the putative eQTL in the 5' region of *CPB2* has proven more challenging as a consequence of strong LD between promoter polymorphisms. One SNP in the 5' region (-2599C > G, rs34813434) that was suggested to contribute to the regulation of TAFI-Ag in the *trans*-ethnic analysis³⁹ is in high LD with our lead SNP ($R^2 = 0.96$, $D' = 1$; based on the 1000 Genomes Project CEU population). However, promoter deletion experiments in HepG2-transfected cells do not support a functional role for this SNP.⁴⁴ Given that our lead SNP rs56734909 is located 490 bp upstream of rs34813434, it was not analysed in the promoter deletion experiments, and as it is within a predicted enhancer element we evaluated its putative effect on regulatory motifs. According to HaploReg, enhancer histone marks were identified in liver tissue where *CPB2* is expressed, and eight regulatory motifs are altered by this SNP. Although speculative, these data suggest that rs56734909 may be the functional 5' SNP affecting levels, a hypothesis that requires validation through functional experiments.

For the GWAS of TAFI-AP, the lead SNP in the *CPB2* locus, rs940, is located within the 3' UTR and has previously been

shown to associate with TAFI-Ag levels (+1542C > G).^{19,22} This SNP is in perfect LD with four SNPs predicted to be located within two putative enhancers (rs2296641, rs3783202 and rs1409435 in enhancer GH130046056; and rs2897027 in enhancer GH130046061) and high LD with three additional putative enhancer SNPs (rs4942470 in GH130046061; rs7139571 in GH130046087; and rs7989892 in GH130046056). Two known common SNPs in *CPB2* lead to amino acid substitutions in TAFI, Thr147Ala (rs3742264) and Thr325Ile (rs1926447). Individuals with Ile-325 variants have a more stable TAFIa enzyme with an extended half-life,⁴⁵ whereas the Ala-147 variant does not affect the stability. Both were significantly associated with TAFI-AP in the unconditioned analysis (rs3742264, $P = 1.010 \times 10^{-13}$ and rs1926447, $P = 7.98 \times 10^{-26}$) but not in the analysis conditioned on rs940 (rs3742264, $P = 3.19 \times 10^{-4}$ and rs1926447, $P = 0.302$). Because SNP rs940 is tightly linked with rs1926447 ($R^2 = 0.83$, $D' = 1$; based on the 1000 Genomes Project CEU population) and multiple SNPs in putative enhancers, the question remains open as to which one is functional.

It is of note that the antisense lncRNA *CPB2-AS1* is located on the opposite DNA strand and fully overlapping with the *CPB2* gene. Antisense lncRNAs can modulate expression of their sense transcripts through various mechanisms (reviewed in the study of Villegas and Zaphiropoulos⁴⁶). For example, sense RNA and antisense lncRNA transcripts can hybridize and form RNA duplexes which can interfere with splicing, RNA editing and alter mRNA stability. Therefore, it is plausible that some SNPs associated with intact TAFI and/or TAFI-AP levels may exert their effects via the *CPB2-AS1* transcript rather than *CPB2* gene. In line with this, rs1087 and rs940 associated with intact TAFI and TAFI-AP, respectively, were found to be eQTLs for *CPB2-AS1* in the GTEx database. However, to our knowledge, the putative functional effect from *CPB2-AS1* on *CPB2* transcript level has not been reported upon in the literature and is unknown.

Taken together, polymorphisms within *CPB2* were found to explain only a modest amount of the variation in intact TAFI (5.4%) and TAFI-AP (3.8%) levels, (above age, sex and case-control status). This is much lower than observed in older works that used immunological assays that measured 'total' TAFI (TAFI-Ag, i.e. intact TAFI as well as the various cleavage products). Many of these assays were later demonstrated to have decreased reactivity toward the TAFI Ile325 isoform, and as a result overestimated the TAFI heritability and effects associated with *CPB2* polymorphisms.^{16,17,19} Two small studies ($n < 300$) that used isoform-independent TAFI assays reported a combined variance estimate for *CPB2* SNPs of 15 to 25% in univariate haplotype analyses.^{38,39} While higher than our findings, the difference in variance estimates could be due in part to the different methodologies used in the measurement of TAFI, the different populations studied and the fact that different covariates were used in the calculation/models.

Using GWAS, we also identified one novel variant associated with TAFI-AP concentrations on chromosome 3 (rs140102162) and several suggestive loci. However, despite the fact that rs140102162 was genome-wide significant ($P = 1.3 \times 10^{-8}$), it was a solitary SNP within an intergenic

region. Similarly, most suggestive findings were also due to solitary SNPs. We were unable to identify any eQTLs for these variants in any tissue in publically available resources. Thus, apart from *CPB2*, we did not identify any strong evidence for additional candidate loci for determining plasma TAFI concentrations. Combined with the fact that rs140102162 and the majority of suggestive variants were low frequency, we did not proceed into replication as this would require very large sample sizes.

CPB2 was also significantly associated with intact TAFI and suggestively associated with TAFI-AP in the gene-based analysis ($P = 2.8 \times 10^{-8}$ and 7.2×10^{-6} , respectively), and this was due to a rare coding variant. This association was independent of the more common variants at this locus. Carriers of the rs140446990 (Asp177Gly) mutation had significantly lower intact TAFI and TAFI-AP levels than noncarriers. Since intact TAFI and TAFI-AP are moderately correlated (Spearman's $Rho = 0.33$), this indirectly suggests that the SNP has no direct bearing on the extent of activation (i.e.: TAFI-AP, amino acids residues 1–92), and simply reflects this interrelationship.

The gene-based analyses also showed completely novel associations for TAFI-AP with five genes. The strongest signal was for *SGPL1*, which encodes the enzyme SPL. SPL has been directly implicated in various physiological and pathological processes, including cell stress responses, cancer, immunity, hematopoietic function, muscle homeostasis, inflammation and development. Furthermore, SPL irreversibly degrades the lipid signaling molecule S1P, which has recently emerged as a critical mediator linking the coagulation factor system to vascular inflammation⁴⁷ and has been implicated in various cardiovascular events such as myocardial infarction and stroke.^{48–50} Thus, it would be of interest to seek replication and also to investigate associations between rare variants in *SGPL1* and cardiovascular diseases. However, as the MAF is as low as 0.02 to 0.03%, this will require very large datasets genotyped with rare variant information (e.g. exome chips or exome sequencing) and as far as we are aware it is not feasible at this time.

The strengths of this study include that approximately 10 million markers spread throughout the genome, covering the full allelic spectrum of common variants (assessed via GWAS) and rare variants (assessed via gene-based testing) were genotyped in 3,260 individuals with standardized and well-characterized TAFI assays. Despite these strengths, there are some limitations which deserve mention. Although this is the largest study on the genetic regulation of intact TAFI and TAFI-AP published to date, it is still small for GWAS standards, and in the future an expansion of the number of study subjects is needed to improve the power of detecting genetic variants related to TAFI. Specifically, this study is still underpowered to detect variants with low MAF in single variant analyses. Although we used gene-based tests to increase power for low-frequency and rare variants, one limitation is that the exome array does not provide complete coverage of all functional variants at each locus. Exome or whole-genome sequencing would be required to completely assess variants associated with TAFI levels. As such, it remains possible that a burden of rare mutations could contribute to plasma TAFI levels. Additionally, it should also be emphasized that the results were

generated in European ancestry populations, and our findings many not be generalizable to populations of different ethnicity. Finally, the results are explorative in nature and clearly require future replication in an independent cohort.

In conclusion, using genome-wide genotype data from a total of 3,260 subjects, we confirmed the *CPB2* locus to be the strongest determinant of plasma TAFI, but showed that the effect was more modest than previously reported. Through gene-based testing, we identified novel putative functional variants within the *CPB2* locus and in five other genes that require future independent replication.

Conflict of Interest

There are no direct or indirect conflicts of interest to declare.

Financial Support

The present study was supported by the Swedish Research Council and grants from the Swedish state (ALF), the Swedish Heart-Lung Foundation and the Swedish Stroke Association. The National Institute of Neurological Disorders and Stroke (NINDS) funded the genotyping of patients included in the SiGN study. PI, Steven Kittner.

Acknowledgements

The authors thank research nurse Ingrid Eriksson for her excellent work and assistance with the study patients and Miet Peeters for the analyses of intact TAFI and TAFI-AP.

What is known about this topic?

- Elevated circulating TAFI concentrations have been reported in patients with cardiovascular disease and family studies have demonstrated that plasma TAFI concentrations are heritable.
- Several common single nucleotide polymorphisms (SNPs) located within the gene encoding TAFI (*CPB2*) have been described and some are reported to be associated with plasma TAFI concentrations and risk of arterial and venous thrombotic disease.

What does this paper add?

- This is the first genome-wide association study and the first study that used gene-based tests of low-frequency and rare variants to identify the genetic basis for the heritability of circulating TAFI concentrations.
- We verified *CPB2* to be the primary determinant of TAFI concentrations and identified putative secondary loci (candidate variants and genes) that require independent validation.

References

- 1 Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. *J Clin Invest* 2002;110(09):1275–1282

- 2 Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. *Clin Biochem* 2007;40(07):431–442
- 3 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. *J Biol Chem* 1996;271(28):16603–16608
- 4 Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. *J Biol Chem* 1999;274(49):35046–35052
- 5 Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. *J Biol Chem* 1998;273(42):27176–27181
- 6 Marx PF, Dawson PE, Bouma BN, Meijers JC. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. *Biochemistry* 2002;41(21):6688–6696
- 7 Franco RF, Fagundes MG, Meijers JC, et al. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. *Haematologica* 2001;86(05):510–517
- 8 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. *Blood* 2000;95(09):2855–2859
- 9 Santamaría A, Martínez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. *Haematologica* 2004;89(07):880–881
- 10 Schroeder V, Wilmer M, Buehler B, Kohler HP. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. *Thromb Haemost* 2006;96(02):236–237
- 11 Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. *Arterioscler Thromb Vasc Biol* 2007;27(04):955–962
- 12 Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. *J Thromb Haemost* 2005;3(10):2211–2218
- 13 Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J. Thrombin-activatable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. *Stroke* 2003;34(04):1038–1040
- 14 Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. *Thromb Haemost* 2000;83(06):902–905
- 15 Ariëns RAS, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. *Lancet* 2002;359(9307):667–671
- 16 Bladbjerg EM, de Maat MPM, Christensen K, Bathum L, Jespersen J, Hjelmberg J. Genetic influence on thrombotic risk markers in the elderly—a Danish twin study. *J Thromb Haemost* 2006;4(03):599–607
- 17 Peetz D, Victor A, Adams P, et al. Genetic and environmental influences on the fibrinolytic system: a twin study. *Thromb Haemost* 2004;92(02):344–351
- 18 Sabater-Lleal M, Buil A, Souto JC, et al. A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels. *Hum Genet* 2008;124(01):81–88
- 19 Tréguet DA, Aubert H, Henry M, et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. *Hum Genet* 2001;109(02):191–197
- 20 Warren DM, Cole SA, Dyer TD, et al. A locus on chromosome 13 influences levels of TAFI antigen in healthy Mexican Americans. *Hum Biol* 2006;78(03):329–339
- 21 Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. *Blood* 2001;98(06):1992–1993
- 22 Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. *Blood* 2001;97(07):2053–2058
- 23 Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. *Thromb Haemost* 1998;80(06):949–955
- 24 Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. *Arterioscler Thromb Vasc Biol* 2003;23(06):1122–1127
- 25 Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. *Br J Haematol* 2004;124(05):659–665
- 26 Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. *Arterioscler Thromb Vasc Biol* 2006;26(02):423–428
- 27 Söderholm M, Almgren P, Jood K, et al. Exome array analysis of ischaemic stroke: results from a southern Swedish study. *Eur J Neurol* 2016;23(12):1722–1728
- 28 Jood K, Ladenvall C, Rosengren A, Blomstrand C, Jern C. Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. *Stroke* 2005;36(07):1383–1387
- 29 Li C, Engström G, Hedblad B, Berglund G, Janzon L. Risk factors for stroke in subjects with normal blood pressure: a prospective cohort study. *Stroke* 2005;36(02):234–238
- 30 NINDS Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. *Lancet Neurol* 2016;15(02):174–184
- 31 Goldstein JL, Crenshaw A, Carey J, et al; Swedish Schizophrenia Consortium; ARRA Autism Sequencing Consortium. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. *Bioinformatics* 2012;28(19):2543–2545
- 32 McCarthy S, Das S, Kretzschmar W, et al; Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* 2016;48(10):1279–1283
- 33 Delaneau O, Howie B, Cox AJ, Zagury JF, Marchini J. Haplotype estimation using sequencing reads. *Am J Hum Genet* 2013;93(04):687–696
- 34 Lee S, Emond MJ, Bamshad MJ, et al; NHLBI GO Exome Sequencing Project—ESP Lung Project Team. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. *Am J Hum Genet* 2012;91(02):224–237
- 35 Lonsdale J, Thomas J, Salvatore M, et al; GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45(06):580–585
- 36 Veyrieras JB, Kudaravalli S, Kim SY, et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. *PLoS Genet* 2008;4(10):e1000214
- 37 Westra H-J, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat Genet* 2013;45(10):1238–1243
- 38 Frère C, Morange PE, Saut N, et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. *Thromb Haemost* 2005;94(02):373–379
- 39 Frère C, Tregouet DA, Morange PE, et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. *Blood* 2006;108(05):1562–1568

- 40 Biswas A, Ranjan R, Meena A, et al. TAFI antigen level variability in young healthy Asian Indians; first report from Asia. *Clin Biochem* 2008;41(09):750–753
- 41 Boffa MB, Maret D, Hamill JD, et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. *Blood* 2008;111(01):183–189
- 42 Maret D, Boffa MB, Brien DF, Nesheim ME, Koschinsky ML. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. *J Thromb Haemost* 2004;2(11):1969–1979
- 43 Morange PE, Tregouet DA, Frere C, et al; Prime Study Group. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. *J Thromb Haemost* 2005;3(07):1503–1510
- 44 Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). *Biochemistry* 1999;38(20):6547–6558
- 45 Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. *J Biol Chem* 2002;277(02):1021–1030
- 46 Villegas VE, Zaphiropoulos PG. Neighboring gene regulation by antisense long non-coding RNAs. *Int J Mol Sci* 2015;16(02):3251–3266
- 47 Mahajan-Thakur S, Böhm A, Jedlitschky G, Schrör K, Rauch BH. Sphingosine-1-phosphate and its receptors: a mutual link between blood coagulation and inflammation. *Mediators Inflamm* 2015;2015:831059
- 48 Knapp M. Cardioprotective role of sphingosine-1-phosphate. *J Physiol Pharmacol* 2011;62(06):601–607
- 49 Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. *Ann Neurol* 2011;69(01):119–129
- 50 Zhao Z, Wang R, Huo Z, Li C, Wang Z. Characterization of the anticoagulant and antithrombotic properties of the Sphingosine 1-phosphate mimetic FTY720. *Acta Haematol* 2017;137(01):1–6